Want to see AU:CBL full AI Analyst Report?
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$28.50M
Enterprise ValueAU$25.95M
Total Cash (Recent Filing)AU$3.06M
Total Debt (Recent Filing)AU$258.10K
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding445,317,660
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained 16% top-line growth indicates genuine demand for Control Bionics' assistive-tech offerings and steady market adoption. Over 2–6 months this supports scalable unit economics if operating costs are controlled, enabling eventual margin recovery and reinvestment in product development.
Conservative LeverageA low debt profile preserves financial flexibility and reduces solvency risk, allowing the company to weather revenue cyclicality and prioritize R&D or targeted commercialization without heavy interest burdens. This balance sheet strength supports sustainable operations over the medium term.
Niche Assistive-Tech FocusOperating in specialized assistive technology provides durable competitive positioning: high technical barriers, mission-driven demand, and regulatory/customer stickiness. This structural niche supports long-term addressable market growth and differentiated product pricing versus general consumer electronics.
Bears Say
Negative Operating Cash FlowOngoing negative operating cash flow undermines internal funding of operations and capex, forcing reliance on external capital. Over months this constrains strategic flexibility, delays scaling initiatives, and can increase refinancing risk if cash generation doesn't improve or costs aren't curtailed.
Persistent UnprofitabilityDespite revenue growth, consistent net losses and negative EBIT margins show the company isn't converting sales into sustainable profits. Persistent unprofitability erodes shareholder value over time and suggests structural cost or pricing issues that must be resolved to achieve durable financial health.
Rising Reliance On External FundingDeclining free cash flow and negative operating cash flows increase the probability of additional equity or debt raises. Over the medium term this can dilute shareholders, raise financing costs, and limit the company's ability to invest opportunistically or execute long-term product roadmaps without external support.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$28.50M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 17 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 445,317,660 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CBL Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth AU$30.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.36%
Trailing 12-Months
Company Description
Control Bionics Ltd.
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Compumedics Limited
―
Neurotech International
―
EMvision Medical Devices Ltd.
―